Recently, our previous studies have demonstrated that PTX3 is a downstream target of CEBPD and contributes to inflammation-related disorders, such as atherosclerosis [20], Alzheimer's disease [21], rheumatoid arthritis [22], invasion and metastasis of cancer, and drug-resistant cancers [16]. This evidence concerns the gene PTX3 and rheumatoid arthritis.